Dr Reddy’s Laboratories announced today that it launched Paricalcitol capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of ZEMPLAR® (Paricalcitol) Capsules in the US market on Tuesday (June 24), following approval from the United States Food & Drug Administration (USFDA).
The Zemplar brand and its generic version recorded US sales of approximately $109.6 million for the most recent 12 months ending in March 2014, according to IMS Health.
Dr Reddy’s Paricalcitol capsules are available in bottle counts of 30.